Apellis Pharmaceuticals, Inc. Logo

Apellis Pharmaceuticals, Inc.

Biopharmaceutical company developing therapies by targeting the complement cascade.

APLS | US

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
100 FIFTH AVENUE, 2451 WALTHAM

Description

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing therapies for a broad range of debilitating diseases by targeting the complement cascade. The company's scientific approach is centered on controlling C3, a central protein in this part of the immune system, to treat conditions driven by its overactivation. Apellis's development efforts are concentrated in the areas of ophthalmology, hematology, and nephrology. Its portfolio of approved medicines includes SYFOVRE® (pegcetacoplan injection) for the treatment of geographic atrophy (GA) and EMPAVELI® (pegcetacoplan) for other serious, complement-driven diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2026-01-09 19:48
PRIMARY DOCUMENT
English ZIP 7.6 KB
2026-01-06 22:06
PRIMARY DOCUMENT
English ZIP 6.7 KB
2026-01-05 22:42
PRIMARY DOCUMENT
English ZIP 7.8 KB
2026-01-05 22:39
PRIMARY DOCUMENT
English ZIP 7.3 KB
2026-01-05 22:38
PRIMARY DOCUMENT
English ZIP 7.2 KB
2026-01-05 22:37
PRIMARY DOCUMENT
English ZIP 7.3 KB
2026-01-05 22:36
PRIMARY DOCUMENT
English ZIP 7.2 KB
2026-01-05 22:35
PRIMARY DOCUMENT
English ZIP 7.2 KB
2026-01-05 22:34
PRIMARY DOCUMENT
English ZIP 7.2 KB
2026-01-05 21:06 English ZIP 7.0 KB
2025-12-18 22:06
PRIMARY DOCUMENT
English ZIP 7.1 KB
2025-12-16 16:24 English ZIP 7.2 KB
2025-11-18 16:05
PRIMARY DOCUMENT
English ZIP 7.1 KB
2025-11-17 16:28 English ZIP 7.2 KB
2025-11-14 21:45 English ZIP 11.8 KB

Automate Your Workflow. Get a real-time feed of all Apellis Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Apellis Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Apellis Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Advicenne Logo
A specialty pharmaceutical company developing treatments for rare renal diseases.
France
ALDVI
AegirBio AB Logo
A diagnostics company specializing in therapeutic drug monitoring for biological drugs.
Sweden
AEGIR
Aelis Farma Logo
Biopharmaceutical company developing CB1 receptor inhibitors for CNS disorders.
France
AELIS
AEON Biopharma, Inc. Logo
Clinical-stage company developing therapeutic applications for botulinum toxins.
United States of America
AEON
AFC-HD AMS Life Science Co.,Ltd. Logo
An OEM of health foods, supplements, and cosmetics with integrated R&D and manufacturing.
Japan
2927
AGENUS INC Logo
A clinical-stage biotechnology company specializing in immuno-oncology therapies.
United States of America
AGEN
AGIOS PHARMACEUTICALS, INC. Logo
Biopharmaceutical company developing therapies for rare and genetically defined diseases.
United States of America
AGIO
AHN-GOOK PHARMACEUTICAL Co., Ltd. Logo
Develops and markets medicines, focusing on respiratory and cardiovascular treatments.
South Korea
001540
Akari Therapeutics Plc Logo
Develops next-gen antibody-drug conjugates using proprietary cancer-killing toxins.
United States of America
AKTX
Akebia Therapeutics, Inc. Logo
A biopharmaceutical company that develops and commercializes therapeutics for kidney disease.
United States of America
AKBA

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.